Compare AU

Compare CURE vs. CGHE

Compare shares and ETFs on the ASX that you can trade on Pearler.

S&P US Biotech

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are CURE and CGHE. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.

Community Stats

CURE

CGHE

Popularity

Low

Low

Pearlers invested

82

1

Median incremental investment

$619.50

$2,594.00

Median investment frequency

Monthly

Monthly

Median total investment

$1,386.48

$2,727.95

Average age group

> 35

> 35


Key Summary

CURE

CGHE

Strategy

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

N/A

Top 3 holdings

Natera Inc (3.33 %)

Incyte Corp (2.95 %)

Gilead Sciences Inc (2.81 %)

Claremont Global Fund (Hedged) (Managed Fund) (100 %)

Top 3 industries

Health Care (100.00 %)

Other (10.24 %)

Top 3 countries

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

Management fee

0.45 %

0 %


Key Summary

CURE

CGHE

Issuer

Global X

Tracking index

S&P Biotechnology Select Industry

Asset class

ETF

Stock

Management fee

0.45 %

0 %

Price

$51.50

$1.815

Size

$36.301 million

N/A

10Y return

N/A

N/A

Annual distribution/ dividend yield (5Y)

4.24 %

- %

Market

ASX

ASX

First listed date

12/11/2018

11/02/2024

Purchase fee

$6.50

$6.50


Community Stats

CURE

CGHE

Popularity

Low

Low

Pearlers invested

82

1

Median incremental investment

$619.50

$2,594.00

Median investment frequency

Monthly

Monthly

Median total investment

$1,386.48

$2,727.95

Average age group

> 35

> 35


Pros and Cons

CURE

CGHE

Pros

  • Exposure to more markets and sectors

  • Higher dividend/distribution yield

  • Higher price growth

Cons

  • Lower price growth

  • Exposure to 1 market and 1 sector only

  • Lower dividend/distribution yield

CURE

CGHE

Exposure to more markets and sectors

Exposure to 1 market and 1 sector only

Lower price growth

Higher price growth

Higher dividend/distribution yield

Lower dividend/distribution yield

Home